New therapeutic perspectives with clevidipine: An ultra-short-acting intravenous Ca2+ channel blocker

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1449-1457

  Gradman, Alan H ^a   Vivas, Yoel ^a  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Ca2+ channel blockers; Clevidipine; Hypertensive emergencies; Perioperative hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; ENALAPRILAT; FELODIPINE; FENOLDOPAM; GLYCERYL TRINITRATE; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT; PYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEART SURGERY; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERIOPERATIVE PERIOD; RENAL PROTECTION; UNSPECIFIED SIDE EFFECT; ANIMAL; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; TIME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; INFUSIONS, INTRAVENOUS; PYRIDINES; TIME FACTORS;

EID: 34548578910     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1449     Document Type: Article

References (32)

1. VARON J, MARIK PE: Clinical review: the management of hypertensive crises. Crit. Care (2003) 7(5):374-384.
2. ERICSSON H, FAKT C, JOLIN-MELLGARD A et al.: Clinical and pharmacokinetic results with a new acting-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br. J. Clin. Pharmacol. (1999) 47:531-538.
3. ERICSSON H, THOLANDER B, BJORKMAN JA, NORDLANDER M, REGARDH CG: Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab. Dispos. (1999) 27:558-564.
4. GODFRAIND T, SALOMONE S, DESSY C, VERHELT B, DION R, SCHOEVAERTS JC: Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. (1992) 205:S34-S41.
5. NORDLANDER M, SJOQUIST PO, ERICSSON H, RYDEN L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. (2004) 22(3):227-250.
6. SEGAWA D, SJOQUIST PO, NORDLANDER M, WANG QD, GONON A, RYDEN L: Cardiac inotropic versus chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur. J. Pharmacol. (1999) 10;380(2-3):123-128.
7. ERICSSON H, THOLANDER B, REGARDH CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man. Eur. J. Pharm. Sci. (1999) 8:29-37.
8. ERICSSON H, SCHWIELER J, LINDMARK B, LÖFDAHL P, THULIN T, REGÅRDH C: Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality (2001) 13:130-134.
9. ZHANG JG, DEHAL SS, HO T et al.: Human cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite h152/ 81. Drug Metab. Dispos. (2006) 34:734-737.
10. WANG QD, SAGAWA D, ERICSSON H, SJOQUIST PO, JOHANSON L, RYDEN L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: Part I. J. Cardiovasc. Pharmacol. (2002) 40(2):228-234.
11. SAGAWA D, SJOQUIST PO, WANG QD, GONON A, RYDEN L: Tune-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J. Cardiovasc. Pharmacol (2002) 40(3):339-345.
12. GOURINE AV, PERNOW J, POPUTNIKOV DM, SJOQUIST PO: Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J. Cardiovasc. Pharmacol. (2002) 40:564-570.
13. ODENSTEDT J, MANSSON C, GRIP L: Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J. Cardiovasc. Pharmacol. (2004) 44:407-415.
14. STEPHENS CT, JANDHYALA BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin. Exp. Hypertens. (2002) 24:301-313.
15. ADAMS HP, ADAMS RJ, BROTT T et al.: Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 34:1056.
16. NORDLANDER M, BJORKMAN JA, REGARDH CG, THALEN P: Pharmacokinetics and hemodynamic effects of an ultrashort-acting calcium antagonist. Br. J. Anaesth. (1996) 76(Suppl. 1):A24.
17. SCHWIELER JH, ERICSSON H, LOFDAHL P, THULIN T, KAHAN T: Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J. Cardiovasc. Pharmacol. (1999) 34(2):268-274.
18. BAILEY JM, LU W, LEVY JH et al.: Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology (2002) 96:1086-1094.
19. LEVY JH, MANCAO MY, GITTER R, GRIGORE AM, NEWMAN MF: Clevidipine effectively and rapidly controls elevated blood pressure preoperatively in cardiac surgery patients. Anesthesiology (2005) 103:A354 (Abstract).
20. SINGLA N, WARLTIER DC, LUMB PD, SLADEN RN: Clevidipine is effective in rapidly controlling elevated blood pressure postoperatively in cardiac surgery patients. Anesthesiology (2005) 103:A292 (Abstract).
21. POWROZNYK AV, VUYLSTEKE A, NAUGHTON C et al.: Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur. J. Anaesthesiol. (2003) 20(9):697-703.
22. KIELER-JENSEN N, JOLIN-MELLGÅRD Å, NORDLANDER M, RICKSTEN SE: Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol. Scand. (2000) 44:186-193.
23. ARONSON S, DYKE CM, KEREIAKES D, CHEUNG A, NEWMAN M: Blood pressure control with clevidipine compared to nitroglycerin in the treatment of perioperative hypertension: primary results from the randomized ECLIPSE trial. J. Am. Coll. Cardiol. (2007) 49:A315-419A.
24. ELLIOT WJ: Clinical features in the management of selected hypertensive emergencies. Prog. Cardiovasc. Dis. (2006) 48:316-325.
25. MURPHY MB, MURRAY C, SHORTEN GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N. Engl. J. Med. (2001) 22;345(21):1548-1557.
26. FISCHELL TA, MAHESHWARI A: Current applications for nicardipine in invasive and interventional cardiology. J. Invasive Cardiol. (2004) 16(8):428-432.
27. GROSSMAN E, MESSERLI FH, GRODZICKI T et al.: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA (1996) 276:1328-1331.
28. ERSTAD BL, BARLETTA JF: Treatment of hypertension in the perioperative patient. Ann. Pharmacother. (2000) 34:66-79.
29. GRADMAN AH, VIVAS Y: New drugs for hypertension: what do they offer? Curr. Hypertens. Rep. (2006) 8(5):425-432.
30. PRYS-ROBERTS C, MELOCHE R, FOEX P: Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br. J. Anaesth. (1971) 43:122.
31. HOWELL SJ, HEMMING AE, ALLMAN KG, GLOVER L, SEAR JW, FOEX P: Predictors of postoperative myocardial ischemia. The role of intercurrent arterial hypertension and other cardiovascular risk factors. Anaesthesia (1997) 52:107-111.
32. CURRAN MP, ROBINSON DM, KEATING GM: Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications. Drugs (2006) 66(13):1755-1782.